The sGC-stimulator Riociguat for the treatment of Raynaud's phenomenon: A single-dose, double-blind, randomized, placebo-controlled cross-over study (DIGIT)

Background Raynaud’s phenomenon (RP) is a coldor stress-triggered digital ischemia caused by vasoconstriction in the digital blood vessels, severely affecting patient’s life. Medical therapeutic options for RP are limited and commonly unsatisfactory, with a large number of patients not responding to currently available treatment. In the present study we investigated the safety, efficacy and pharmacokinetics of a single dose of the soluble guanylate cyclase (sGC)-stimulator riociguat in patients with RP in a double-blind, randomized, placebo-controlled cross-over fashion.